Dendreon
Corporate brand
UnclaimedDendreon is a biotechnology company best known for Provenge, an autologous cellular immunotherapy for advanced prostate cancer.
Last updated August 26, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Dendreon Pharmaceuticals is a biotechnology company associated with the development and commercialization of Provenge, the brand name for sipuleucel-T. Provenge is an autologous cellular immunotherapy designed for certain patients with advanced prostate cancer. Rather than being a conventional mass-manufactured drug, it is made using a patient's own immune cells, which are collected, exposed outside the body to a recombinant fusion protein involving prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor, and then returned to the patient. The process was intended to stimulate an immune response against prostate-cancer-associated antigens. The company began as Activated Cell Therapy in Mountain View, California. It was established by William Haseltine, Edgar Engleman, and Richard Strober after financing from Health Care Ventures. The business later adopted the Dendreon name and relocated to Seattle under the leadership of Christopher Henney. Its name referred to dendritic cells, a class of antigen-presenting immune cells central to the company's technology platform. Dendreon's principal scientific concept was a platform sometimes described as Dendreon Cassette Technology. The approach linked a disease-associated target antigen to an immune-signaling or recognition component, with the aim of enabling antigen-presenting cells to generate a targeted immune response. Provenge used prostatic acid phosphatase as the disease-associated antigen and GM-CSF as the immune-stimulating component. Dendreon also investigated whether the platform could be adapted to other diseases by substituting different target antigens, although Provenge remained the company's commercially important product. The path to approval was lengthy. Early clinical work reported immune responses and changes in prostate-specific antigen measurements. Dendreon built a manufacturing facility in Morris Plains, New Jersey, in 2006 to support late-stage development and potential commercial production. The U.S. Food and Drug Administration accepted the company's biologics application in January 2007. An FDA advisory committee later voted that Provenge appeared reasonably safe and that the submitted evidence provided substantial evidence of effectiveness, but the agency requested additional information in May of that year. In 2009, Dendreon announced positive results from a pivotal Phase III study. Detailed results presented at the American Urological Association meeting indicated that patients receiving Provenge had a median survival advantage of approximately 4.1 months over the control group. The FDA granted full approval on April 29, 2010, making Provenge the first approved autologous cellular immunotherapy for cancer in the United States and an important commercial milestone for the broader field of therapeutic cancer vaccines. Commercial execution proved difficult. Provenge required individualized manufacturing and logistics, and its high treatment cost made reimbursement and production capacity significant business issues. In June 2010, disclosure that Medicare officials were considering limits on coverage was followed by a decline in Dendreon's share price. In August 2011, after the company withdrew its sales forecast for Provenge, its stock value fell sharply. The company subsequently faced financial pressure and filed for Chapter 11 bankruptcy protection in November 2014. Dendreon entered a financial restructuring with bondholders, and Valeant Pharmaceuticals received approval in February 2015 to acquire Dendreon's assets. In January 2017, Sanpower Group agreed to acquire the assets from Valeant for $820 million; the transaction closed in June 2017. Dendreon therefore represents both a landmark in personalized cellular medicine and a case study in the manufacturing, reimbursement, forecasting, and financing challenges involved in commercializing individualized cancer therapies.
History
Dendreon originated as Activated Cell Therapy, a biotechnology venture founded in Mountain View, California, by William Haseltine, Edgar Engleman, and Richard Strober. The company obtained early financing from Health Care Ventures and focused on immune-cell-based approaches to treating disease. It later changed its name to Dendreon and moved its operations to Seattle under Christopher Henney. The new name reflected the importance of dendritic cells in its research strategy. The company's central technological idea was to use antigen-presenting cells to generate an immune response against disease-associated targets. Its platform, referred to as Dendreon Cassette Technology, connected a selected antigen with an immune-stimulating component. In the Provenge program, the selected antigen was prostatic acid phosphatase, a protein associated with prostate tissue and prostate cancer, while GM-CSF served as the linked immune-signaling component. Patient immune cells were collected, processed outside the body, incubated with the fusion protein, and reinfused. This individualized production model distinguished Provenge from conventional pharmaceutical products manufactured in standardized batches. Early Provenge studies reported immune responses and reductions in prostate-specific antigen measurements. To support larger trials and potential commercialization, Dendreon established a manufacturing facility in Morris Plains, New Jersey, in 2006. The company submitted a biologics license application that the FDA accepted in January 2007. In March of that year, the FDA's Office of Cellular, Tissue and Gene Therapies advisory committee voted in favor of the product's apparent safety and judged the submitted evidence to provide substantial evidence of effectiveness. The FDA nevertheless requested additional information in May 2007, extending the development and review process. Dendreon announced positive results from a pivotal Phase III trial in April 2009. The study compared Provenge with a control consisting of autologous cells that did not receive the active GM-CSF/prostatic-acid-phosphatase fusion protein. The detailed results presented later that month indicated an average survival advantage of approximately 4.1 months for treated patients. On April 29, 2010, the FDA approved Provenge for advanced prostate cancer. The approval was historically important because Provenge became the first approved cellular immunotherapy of its kind for cancer in the United States. Commercialization exposed the operational difficulty of a personalized cell therapy. Each treatment depended on collection, processing, quality control, and return of a particular patient's cells. The business also faced questions about reimbursement and the treatment's high price. In June 2010, public attention focused on a leaked Medicare email concerning a possible cap on coverage. In August 2011, Dendreon abandoned its Provenge sales forecast, and the company's stock value fell sharply. These events highlighted the gap between clinical approval and the practical requirements for scaling an individualized therapy. Dendreon investigated whether its platform could be adapted by replacing the prostate-related antigen with targets for other diseases. The company and its collaborators examined antigen selection, tumor-specific targets, post-translational changes, and related immune mechanisms. The available record also associates Dendreon with work involving anticoagulation and immune-process technologies, including acquired patent and asset interests connected with Corvas and Nuvelo. Provenge, however, remained the company's defining commercial product. Financial difficulties eventually led Dendreon to file for Chapter 11 bankruptcy protection in November 2014. The company entered restructuring discussions with certain bondholders. Valeant Pharmaceuticals received approval to purchase Dendreon's assets in February 2015. In January 2017, Sanpower Group agreed to acquire the assets from Valeant for $820 million, and the transaction closed in June 2017. Dendreon's history consequently combines an important scientific first with the financing, manufacturing, reimbursement, and forecasting challenges that can accompany personalized biotechnology products.
- 2017
Sanpower acquisition closes
[1]Sanpower Group's acquisition of Dendreon from Valeant closed in June.
- 2015
Valeant acquires Dendreon assets
[1]Valeant received approval to purchase all Dendreon assets.
- 2014
Chapter 11 bankruptcy filing
[1]Dendreon filed for Chapter 11 protection and began a financial restructuring.
- 2010
Provenge receives FDA approval
[1]The FDA approved sipuleucel-T for advanced prostate cancer on April 29.
- 2009
Phase III survival results presented
[1]Detailed Phase III results for Provenge indicated a median survival benefit of approximately 4.1 months over the control group.
- 2007
Provenge biologics application accepted
[1]The FDA accepted Dendreon's biologics license application for Provenge in January.
- 2007
Advisory committee supports Provenge evidence
[1]An FDA advisory committee voted favorably on the product's safety and effectiveness evidence, but the agency later requested more information.
- 2006
Manufacturing facility established in New Jersey
[1]Dendreon built a Morris Plains, New Jersey, facility to support late-stage Provenge trials and possible commercial production.
Products and positioning
A biotechnology and cellular-immunotherapy brand centered on personalized, patient-specific cancer treatment, especially immune-based therapy for advanced prostate cancer.
Autologous cellular immunotherapy · 2010
Provenge
Provenge is the brand name for sipuleucel-T, a personalized cellular immunotherapy for certain patients with advanced prostate cancer. A patient's immune cells are collected and exposed to a recombinant fusion protein containing prostatic acid phosphatase and GM-CSF. The activated cell product is then returned to the same patient. The therapy became notable as an early approved example of individualized cancer immunotherapy and was designed to stimulate an immune response against a prostate-cancer-associated antigen.
Biotechnology platform
Dendreon Cassette Technology
Dendreon Cassette Technology was the company's platform concept for combining disease-specific target proteins with immune-recognition or immune-stimulating components. The objective was to provide antigen-presenting cells with a programmed target that could be adapted to different diseases. Provenge represented the prostate-cancer application of this broader approach, while other target-antigen applications were investigated during the company's research program.
Brand decisions
2017
Sanpower acquisitionM&ABackground
Sanpower Group agreed to acquire Dendreon from Valeant after the company's restructuring and asset sale.
Action taken
Sanpower acquired the business for $820 million, with the transaction closing in June 2017.
Aftermath
Dendreon became part of Sanpower's healthcare-related holdings.
Acquisition price. $820 million (2017 transaction)
2015
Sale of Dendreon assets to ValeantM&ABackground
The transaction followed Dendreon's bankruptcy and financial restructuring process.
Action taken
Valeant Pharmaceuticals received approval to purchase all Dendreon assets.
Aftermath
Valeant later sold the business and its assets to Sanpower Group.
2014
Chapter 11 restructuringOtherBackground
Dendreon faced financial pressure after the difficult commercial rollout of Provenge and filed for bankruptcy protection.
Action taken
The company entered Chapter 11 and announced restructuring agreements with certain bondholders.
Aftermath
Dendreon's assets were subsequently acquired by Valeant and later by Sanpower Group.
2010
Dendreon proceeds with Provenge commercializationStrategyBackground
FDA approval established Provenge as a commercial therapy, but its individualized manufacturing process required specialized production and distribution capabilities.
Action taken
Dendreon pursued commercialization using dedicated manufacturing capacity and a patient-specific treatment workflow.
Aftermath
The product became an important cellular-immunotherapy milestone, while manufacturing scale, reimbursement, and demand forecasting remained significant commercial challenges.
Recent events
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/dendreon · Editorial policy · How profiles are compiled